Issue 34, 2025

Synergistic chemotherapy and phototherapy co-delivery nanoparticle preparation and anti-triple negative breast cancer study

Abstract

In this study, the amphiphilic polymer HA–ANI, formed by grafting hyaluronic acid (HA) and 6-(2-nitroimidazolyl)hexylamine (ANI), was self-assembled in water to form nanoparticles (NPs), which were modified to obtain dual drug-loaded nanoparticles (P/I NPs) by dialysis loading of paclitaxel (PTX) and IR780. Electron microscopy and dynamic light scattering (DLS) results showed that the P/I NPs presented a near-spherical shape with a size of 221.10 ± 2.31 nm. The drug loading and encapsulation rates of PTX in P/I NPs were 22.73% and 89.23%, respectively, and those of IR780 were 1.11% and 42.44%, respectively. In vitro release experiments demonstrated that NADPH could accelerate the drug release from the NPs. Under the irradiation of an NIR laser, the temperature of the P/I NPs increased significantly. In an in vitro cellular assay treating 4T1 cells for 24 h, the cellular uptake rate of NPs could reach 91.50 ± 3.51%, the 4T1 cell migration rate was 2.68 ± 0.34%, the cell viability was 39.96 ± 0.55%, and the apoptotic cell death rate was 13.93 ± 0.42%. In an in vivo anti-tumor experiment, the inhibition rate of the P/I NPs towards tumors was up to 35.44%; the fluorescence intensity at the tumor site gradually increased with time, and the maximum value appeared within 24 h, indicating that the P/I NPs had a targeting function. The results of H&E staining showed that there was no obvious pathological damage to the main organs of the mice in each group, that means there were no obvious side effects.

Graphical abstract: Synergistic chemotherapy and phototherapy co-delivery nanoparticle preparation and anti-triple negative breast cancer study

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Paper
Submitted
19 Dec 2024
Accepted
26 Mar 2025
First published
11 Aug 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 28298-28312

Synergistic chemotherapy and phototherapy co-delivery nanoparticle preparation and anti-triple negative breast cancer study

F. Yang, H. Liu, Q. Luo, H. Deng, R. Zhang, Y. Yang, H. Yang, H. Wu and X. Tao, RSC Adv., 2025, 15, 28298 DOI: 10.1039/D4RA08899A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements